Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,517

Document Document Title
WO/2019/161280A1
The present disclosure relates to methods and intermediates useful for preparing a compound of formula (I): (I) or a co-crystal, solvate, salt or combination thereof.  
WO/2019/150341A1
The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination w...  
WO/2019/149091A1
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...  
WO/2019/142539A1
A composition comprising a compound represented by formula (I) and a compound represented by formula (III); a curable composition; and a compound. R11 represents an unsubstituted alkyl group. R12, R13, R32, and R33 each independently rep...  
WO/2019/129403A1
The present invention concerns the field of neurodegenerative diseases, and in particular relates to compounds, pharmaceutical compositions and their uses in the protection of neuronal cells from inflammation and from oxidative stress in...  
WO/2019/124154A1
Provided are: a polymerizable liquid-crystal compound suitable for producing positive-C-plate retarder films which have excellent heat resistance and reverse wavelength dispersion characteristics; a polymerizable liquid-crystal compositi...  
WO/2019/111853A1
The present invention addresses the problem of providing a method for producing a dicarboxylic acid monoester with excellent production efficiency, a method for producing a polymerizable liquid crystal compound, and a novel dicarboxylic ...  
WO/2019/108033A1
The present specification provides a compound represented by chemical formula 1, and an organic light emitting element comprising the same.  
WO/2019/087054A1
The present invention relates to novel pharmaceutical composition comprising DPP-4 inhibitor, Alpha-lipoic acid and Vitamin B12. The synergism of DPP-4 inhibitor, Alpha- lipoic acid and Vitamin B12 helps in the treatment of diabetes and ...  
WO/2019/071353A1
A method of reducing glutamate efflux from skeletal muscle by inhibiting system Xc- activity is provided. The method is useful for the treatment of statin-induced myalgia. Pharmaceutical compositions useful to treat statin-induced myalgi...  
WO/2019/061299A1
Provided is a one-step amination reaction for producing an aminomethyl substituted heterocycloalkane, notably (tetrahydrofuran-2, 5-diyl) dimethanamine.  
WO/2019/065043A1
Provided are a compound production method capable of producing a benzothiol compound having little coloration, a composition, and a curable composition. The method is for producing a compound represented by formula (1) and comprises reac...  
WO/2019/044863A1
The present invention provides a cured product which is obtained by curing a curable composition that contains a compound represented by general formula 1, and which has a birefringence ∆n (587 nm) satisfying 0.00 ≤ ∆n (587 nm) ≤...  
WO/2019/017445A1
The present invention addresses the problem of providing: a polymerizable liquid crystal compound which is used in formation of an optically anisotropic membrane having excellent reverse wavelength dispersibility; a polymerizable liquid ...  
WO/2019/017444A1
The present invention addresses the problem of providing: a polymerizable liquid crystal compound which is used in formation of an optically anisotropic membrane having excellent reverse wavelength dispersibility and excellent moist heat...  
WO/2018/167677A1
An object of the present invention is to provide a dithiolane compound or a salt or an N-oxide thereof that controls diseases. The present invention provides a dithiolane compound represented by Formula (1) or a salt or an N-oxide thereo...  
WO/2018/155498A1
The present invention addresses the problem of providing a polymerizable liquid crystal compound that exhibits superior solubility and is used to form an optically anisotropic film exhibiting superior durability, and a method of producin...  
WO/2018/128800A1
The disclosure is directed to compounds of formula (I). Methods of using these compounds, particularly as antimicrobial agents, are also described  
WO/2018/119526A1
The invention relates to a natural biostimulant composition for improving agricultural production, specifically to a biostimulant composition for plants which contains lipoic acid and which is unknown in the prior art, and to a method fo...  
WO/2018/101207A1
The present invention addresses the problem of providing: a polymerizable liquid crystal composition that makes it possible to manufacture an optical film that has excellent light resistance; and an optically anisotropic membrane, an opt...  
WO/2018/049127A1
This invention provides confounds of the formula (I): wherein Y1, Y2 Z, X1, X2, and W are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and Ρ13K/ΑΚΤ/mTor...  
WO/2018/041935A1
The present invention relates to photoinitiator compounds of the formula (1) wherein X is O, S or a direct bond; Y is O, S or CR9R10; R1, R2, R3, R4, R5, R6, R7 and R8 independently of each other are hydrogen, halogen, C1- C18alkyl, C5-C...  
WO/2018/033493A1
The present invention relates to liquid aromatic thioethers, a process for the preparation of the liquid aromatic thioethers, an article comprising the liquid aromatic thioethers as well as the use of the liquid aromatic thioethers as a ...  
WO/2018/024901A1
The present invention relates to the use of a thianthrene-containing polymer as a redox-active electrode material, for example in the form of an electrode slurry, for electrical charge stores, in particular secondary batteries. The inven...  
WO/2018/020974A1
Provided are the following: a sulfonium salt which does not contain a toxic metal and which exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt; a heat- or photo-...  
WO/2018/014408A1
Provided are a light-emitting material, a preparation method therefor and an organic light-emitting diode using said light-emitting material. The light-emitting material has a single structure, a definite molecular weight, a better solub...  
WO/2018/012762A1
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound, according to the present invention, can be used in an organic layer, preferably a light-emitting layer, of an organ...  
WO/2017/202266A1
The present invention relates to a 2-amino-3-substituted mercaptopropionate derivative, a preparation method therefor and a use thereof. The 2-amino-3-substituted mercaptopropionate derivative according to the present invention has a str...  
WO/2017/181004A1
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a ph...  
WO/2017/085733A3
The disclosure herein provides certain analgesic 2,6-xylidine derivatives or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions for...  
WO/2017/098988A1
The present invention provides a polymerizable liquid crystal compound that is highly soluble in various kinds of solvent and that has reverse-wavelength dispersibility or low-wavelength dispersibility. The present invention also provide...  
WO/2017/093558A1
The invention relates to the dyeing of keratin materials using anionic direct dyes containing a disulfide heterocyclic group. The invention relates to a dye composition comprising a fluorescent dye containing a disulfide heterocyclic gro...  
WO/2017/085733A2
The disclosure herein provides a composition of compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1 and its improved processes. The compound of formula 1 or its pharmaceutical acceptable...  
WO/2017/060914A3
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may b...  
WO/2017/078927A1
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...  
WO/2017/060914A2
Penicillamine and its derivatives, composition, methods of synthesizing and using the compound of formula 1 are disclosed. The compounds of formula 1 also comprises of salts, polymorphs, solvates and hydrates thereof. The compounds may b...  
WO/2017/017669A1
The invention relates to Pro-drugs, comprising red-ox-sensitive cleavage sites. The compounds may be utilized in medical practice for targeting of si RNA, antisense oligonucleotides or protein-based therapeutics to the cytoplasmatic comp...  
WO/2017/013420A1
Compounds exhibiting high hole mobility and/or high glass transition temperatures together with favourable HOMO, LUMO and triplet levels are provided which are 2-(4'-Diphenylamino)phenyl-8-(1'-thianthrenyl)- dibenzothiophene and 4-(1-Thi...  
WO/2016/059622A4
Disclosed are linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxie agent, and...  
WO/2016/059622A3
Disclosed are linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxie agent, and...  
WO/2016/126662A1
A composition for treating or preventing disease, especially vascular disease, including a composition chosen from FORMULAS I-VIII, ligands thereof, analogs thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, an ester...  
WO/2016/126667A1
A dietary supplement for daily oral ingestion by adult human beings, said dietary supplement including a palladium-lipoic acid compound. In some embodiments, the dietary supplement also includes glucosamine sulfate. In some embodiments, ...  
WO/2016/115434A1
Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods f...  
WO/2016/111310A1
The present invention addresses the problem of providing a novel compound having an angiotensin converting enzyme (ACE) inhibiting activity. The present invention relates to a compound represented by formula (I-1), a salt of the compound...  
WO/2015/155753A3
Disclosed are linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic group for conjugation of two or more compounds/cytotoxic agents per linker to a cell-binding molecule throu...  
WO/2016/104317A1
The present invention addresses the problems of providing a polymerizable compound which, when added to a polymerizable composition, has high storage stability without causing any crystal precipitation, etc. and of providing a polymeriza...  
WO/2016/073529A1
Provided are compositions, comprising a neolignan, ectoin, and a molecule of Formula I: wherein R1, R2 and R3 are independently H, methyl, ethyl, propyl, or isopropyl; wherein X is S or O. In some cases, the molecule of Formula I is ergo...  
WO/2016/046292A1
The present invention relates to a liquid thioether carboxylic acid ester, a process for the preparation of the liquid thioether carboxylic acid ester, an article comprising the liquid thioether carboxylic acid ester as well as a use of ...  
WO/2016/034963A1
Compounds of the formula (I) (I), wherein X is O, S, a direct bond or CR16R17; Y is O or S; R1, R2, R3, R4, R5, R6, R7 and R8 for example are hydrogen, halogen, C1-C4alkyl, or a group of formula (II) or (III) (II) (III) provided that eit...  
WO/2015/026990A8
The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of CYP26 mediated retinoic acid metabolism. The compositions comprise compounds of formula (I). A repre...  

Matches 1 - 50 out of 2,517